Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...

In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here ...

Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Research indicates that its unique design may allow it to act as an ... as compared to single-receptor agonists. The peptide structure of Tirzepatide includes modifications that are believed ...

Eli Lilly and Co. (LLY) has released detailed findings from the Phase 3 SUMMIT trial, demonstrating that tirzepatide significantly ...

For many patients on tirzepatide, a transformative medication used for weight loss and diabetes, the end of the drug's shortage was anything but welcome news. "I had an anxiety attack," said Maria ...

The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.

Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of tirzepatide ...

In a new Instagram video, the content creator revealed she has lost 58 pounds in the last 10 months thanks to the weight loss drug Tirzepatide and the telehealth service Morph Wellness.